Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LeonaBio, Inc.LONA · Entity 1487 | Director | June 23, 2026 | June 24, 2026 |
| Vaxcyte, Inc.PCVX · Entity 1164 | Director · CHIEF EXECUTIVE OFFICER | September 08, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LeonaBio, Inc.
Report date June 23, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.35 · Expires 2036-06-22 | Direct | 28,000 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 28,000 · Balance 28,000 F1: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.
Vaxcyte, Inc.
Report date September 08, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 429,902 |
Reported balance
After 2026-09-08 transaction · row 1
1 source rowRow 1 · 2026-09-08 · Tax withholding · Disposed 17,056 · Balance 429,902 F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. |
| Common StockSEC Table I · non-derivative | IndirectBy Children's Trust | 133,215 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 133,215 F2: Shares are held directly by a trust for the benefit of the Reporting Person's son. |
| Common StockSEC Table I · non-derivative | IndirectBy Children's Trust | 133,215 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 133,215 F3: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
F2: Shares are held directly by a trust for the benefit of the Reporting Person's son.
F3: Shares are held directly by a trust for the benefit of the Reporting Person's daughter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2024 Filed Aug 5, 2024 20:08 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,308 | $78.78 | $103,048.95 |
DisclosureSEC source: 0001649094-24-000043 · wk-form4_1722888510.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 142,130 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $78.33 to $79.23. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F4 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:08 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,308 | $78.80 | $103,073.54 |
DisclosureSEC source: 0001649094-24-000043 · wk-form4_1722888510.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 142,130 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $78.33 to $79.23. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| July 23, 2024 Filed Jul 24, 2024 21:44 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001649094-24-000039 · wk-form4_1721857439.xml · derivative · entry 6 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 182,327 Underlying: Common Stock · 15,000 shares Expires 2028-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| July 23, 2024 Filed Jul 24, 2024 21:44 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 9,282 | $84.53 | $784,588.90 |
DisclosureSEC source: 0001649094-24-000039 · wk-form4_1721857439.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 478,888 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $84.175 to $84.98. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 23, 2024 Filed Jul 24, 2024 21:44 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 5,718 | $83.83 | $479,322.79 |
DisclosureSEC source: 0001649094-24-000039 · wk-form4_1721857439.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 488,170 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $83.17 to $84.145. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 23, 2024 Filed Jul 24, 2024 21:44 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 15,000 | $2.03 | $30,450.00 |
DisclosureSEC source: 0001649094-24-000039 · wk-form4_1721857439.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 493,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:12 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 557 | $76.89 | $42,825.95 |
DisclosureSEC source: 0001649094-24-000025 · wk-form4_1719951139.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 143,438 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F7 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $76.435 to $77.155. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F6 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:12 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 751 | $75.92 | $57,016.30 |
DisclosureSEC source: 0001649094-24-000025 · wk-form4_1719951139.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 143,995 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $75.43 to $76.285. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F6 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:12 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 634 | $76.86 | $48,728.35 |
DisclosureSEC source: 0001649094-24-000025 · wk-form4_1719951139.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 143,438 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $76.435 to $77.125. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:12 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 674 | $75.84 | $51,119.26 |
DisclosureSEC source: 0001649094-24-000025 · wk-form4_1719951139.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 144,072 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $75.43 to $76.25. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 20:43 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001649094-24-000021 · wk-form4_1719348224.xml · derivative · entry 7 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 197,327 Underlying: Common Stock · 15,000 shares Expires 2028-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 20:43 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 188 | $76.80 | $14,437.46 |
DisclosureSEC source: 0001649094-24-000021 · wk-form4_1719348224.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 478,888 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $76.74 to $76.81. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 20:43 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,471 | $76.17 | $340,565.01 |
DisclosureSEC source: 0001649094-24-000021 · wk-form4_1719348224.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 479,076 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $75.74 to $76.73. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 20:43 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 10,341 | $75.39 | $779,576.97 |
DisclosureSEC source: 0001649094-24-000021 · wk-form4_1719348224.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 483,547 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $74.735 to $75.73. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 20:43 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 15,000 | $2.03 | $30,450.00 |
DisclosureSEC source: 0001649094-24-000021 · wk-form4_1719348224.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 493,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:56 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 224 | $73.43 | $16,449.22 |
DisclosureSEC source: 0001415889-24-015586 · form4-06052024_080635.xml · nonDerivative · entry 6 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 144,746 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F7 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $73.41 to $73.46. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F5 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:56 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 327 | $72.55 | $23,723.20 |
DisclosureSEC source: 0001415889-24-015586 · form4-06052024_080635.xml · nonDerivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 144,970 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F6 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $72.13 to $72.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F5 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:56 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 757 | $71.43 | $54,071.00 |
DisclosureSEC source: 0001415889-24-015586 · form4-06052024_080635.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 145,297 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $70.98 to $71.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F5 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:56 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 117 | $73.46 | $8,594.82 |
DisclosureSEC source: 0001415889-24-015586 · form4-06052024_080635.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 144,746 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:56 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 486 | $72.66 | $35,311.30 |
DisclosureSEC source: 0001415889-24-015586 · form4-06052024_080635.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 144,863 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $72.155 to $73.06. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:56 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 705 | $71.44 | $50,362.38 |
DisclosureSEC source: 0001415889-24-015586 · form4-06052024_080635.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 145,349 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $70.98 to $71.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| May 24, 2024 Filed May 24, 2024 22:55 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 20,900 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001415889-24-014571 · form4-05242024_100527.xml · derivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,900 Underlying: Common Stock · 20,900 shares Expires 2034-05-23 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) May 24, 2025, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 24, 2024. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. Read SEC document |
| May 23, 2024 Filed May 28, 2024 20:22 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001415889-24-014661 · form4-05282024_080505.xml · derivative · entry 6 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 212,327 Underlying: Common Stock · 15,000 shares Expires 2028-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| May 23, 2024 Filed May 28, 2024 20:22 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 8,789 | $69.84 | $613,823.76 |
DisclosureSEC source: 0001415889-24-014661 · form4-05282024_080505.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 477,847 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $69.56 to $71.34. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 23, 2024 Filed May 28, 2024 20:22 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 6,211 | $68.84 | $427,583.87 |
DisclosureSEC source: 0001415889-24-014661 · form4-05282024_080505.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 486,636 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $68.32 to $69.31. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 23, 2024 Filed May 28, 2024 20:22 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 15,000 | $2.03 | $30,450.00 |
DisclosureSEC source: 0001415889-24-014661 · form4-05282024_080505.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 492,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:18 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 46 | $63.84 | $2,936.64 |
DisclosureSEC source: 0001415889-24-012165 · form4-05032024_080551.xml · nonDerivative · entry 6 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 146,054 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F6 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:18 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 582 | $62.07 | $36,122.41 |
DisclosureSEC source: 0001415889-24-012165 · form4-05032024_080551.xml · nonDerivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 146,100 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F7 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $61.755 to $62.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F6 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:18 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 680 | $61.28 | $41,671.76 |
DisclosureSEC source: 0001415889-24-012165 · form4-05032024_080551.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 146,682 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $60.76 to $61.73. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F6 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:18 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 72 | $63.87 | $4,598.64 |
DisclosureSEC source: 0001415889-24-012165 · form4-05032024_080551.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 146,054 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:18 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 508 | $62.01 | $31,499.05 |
DisclosureSEC source: 0001415889-24-012165 · form4-05032024_080551.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 146,126 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $61.785 to $62.445. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:18 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 728 | $61.25 | $44,590.73 |
DisclosureSEC source: 0001415889-24-012165 · form4-05032024_080551.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 146,634 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $60.76 to $61.46. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| April 23, 2024 Filed Apr 25, 2024 20:52 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001415889-24-011522 · form4-04252024_080442.xml · derivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 225 Underlying: Common Stock · 15,000 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| April 23, 2024 Filed Apr 25, 2024 20:52 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 15,000 | $61.92 | $928,845.00 |
DisclosureSEC source: 0001415889-24-011522 · form4-04252024_080442.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 477,847 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $61.49 to $62.355. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 23, 2024 Filed Apr 25, 2024 20:52 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 15,000 | $1.79 | $26,850.00 |
DisclosureSEC source: 0001415889-24-011522 · form4-04252024_080442.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 492,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:21 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3 | $68.10 | $204.30 |
DisclosureSEC source: 0001415889-24-009995 · form4-04032024_080407.xml · nonDerivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 147,362 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F6 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:21 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 415 | $67.24 | $27,906.26 |
DisclosureSEC source: 0001415889-24-009995 · form4-04032024_080407.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 147,365 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F7 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $67.025 to $67.44. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F6 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:21 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 890 | $66.45 | $59,137.83 |
DisclosureSEC source: 0001415889-24-009995 · form4-04032024_080407.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 147,780 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $66.02 to $66.87. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F6 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:21 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 324 | $67.27 | $21,796.45 |
DisclosureSEC source: 0001415889-24-009995 · form4-04032024_080407.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 147,362 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $67.14 to $68.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:21 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 984 | $66.52 | $65,456.66 |
DisclosureSEC source: 0001415889-24-009995 · form4-04032024_080407.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 147,686 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $66.05 to $66.97. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 20:44 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001415889-24-009214 · form4-03272024_080342.xml · derivative · entry 6 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,225 Underlying: Common Stock · 15,000 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 20:44 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,550 | $67.50 | $104,617.25 |
DisclosureSEC source: 0001415889-24-009214 · form4-03272024_080342.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 477,847 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $67.415 to $67.695. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 20:44 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 13,450 | $66.87 | $899,361.15 |
DisclosureSEC source: 0001415889-24-009214 · form4-03272024_080342.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 479,397 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $66.42 to $67.405. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 20:44 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 15,000 | $1.79 | $26,850.00 |
DisclosureSEC source: 0001415889-24-009214 · form4-03272024_080342.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 492,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 20:22 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001415889-24-007804 · form4-03132024_080307.xml · derivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,327 Underlying: Common Stock · 65,000 shares Expires 2028-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 20:22 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 65,000 | $2.03 | $131,950.00 |
DisclosureSEC source: 0001415889-24-007804 · form4-03132024_080307.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 477,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2024 Filed Mar 5, 2024 02:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 7,967 | $71.55 | $570,038.85 |
DisclosureSEC source: 0001415889-24-006472 · form4-03052024_020352.xml · nonDerivative · entry 8 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 412,847 F10 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 02:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 351 | $74.78 | $26,247.43 |
DisclosureSEC source: 0001415889-24-006472 · form4-03052024_020352.xml · nonDerivative · entry 7 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 148,670 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F6 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $74.55 to $74.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F8 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 02:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 591 | $73.59 | $43,491.69 |
DisclosureSEC source: 0001415889-24-006472 · form4-03052024_020352.xml · nonDerivative · entry 6 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 149,021 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F9 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $73.42 to $73.93. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F8 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 02:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 366 | $72.97 | $26,707.02 |
DisclosureSEC source: 0001415889-24-006472 · form4-03052024_020352.xml · nonDerivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 149,612 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F7 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $72.40 to $73.26. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F8 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.